Scarinci Hollenbeck, LLC, LLCScarinci Hollenbeck, LLC, LLC

Firm Insights

Will DEA Proposal Put Psychedelics on the Map or Not?

Author: Daniel T. McKillop

Date: October 13, 2021

Key Contacts

Back

The DEA is proposing a massive increase in the production quotas of cannabis, psilocin, and psilocybin (“magic mushrooms”) for research purposes, with the intent of aiding in the development of new federally approved therapeutic medications…

The Drug Enforcement Administration (DEA) is proposing a massive increase in the production quotas of cannabis, psilocin, and psilocybin (“magic mushrooms”) for research purposes, with the intent of aiding in the development of new federally approved therapeutic medications. The proposal highlights the growing acceptance that Schedule I substances like marijuana and psilocybin may hold great medical promise as therapeutics.

What Is Psilocybin?

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. Psilocybin and other psychedelics are on Schedule 1 of the federal Controlled Substances Act (CSA), just like cannabis. The designation is given to substances having “no currently accepted medical use and a high potential for abuse.”

Nonetheless, studies have shown that psilocybin has the potential to treat a variety of psychiatric and behavioral disorders, including depression, obsessive-compulsive disorder, smoking cessation, alcohol and drug addiction, cluster headaches, and cancer-related or other end-of-life psychological distress. Cancer-related psilocybin therapy is widely regarded as the most promising areas of research for the drug.

Given its potential benefits, efforts are underway to decriminalize the drug and make it easier to pursue further medical research. Decriminalization of psychedelics via local/municipal legislation is already gaining momentum.  Notably, New Jersey Gov. Phil Murphy signed legislation in February reducing penalties for possession of up to an ounce of psilocybin mushrooms by reclassifying the infraction to a disorderly person’s offense.

DEA Proposed Adjustments to Aggregate Production Quotas

Section 306 of the CSA requires the Attorney General to establish aggregate production quotas (APQs) for each basic class of controlled substance listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of DEA.

The DEA’s recent proposal calls for significant increases to the APQs of the schedule I substances psilocybin, psilocin, marihuana, and marihuana extract. According to the DEA, the proposed increases are “directly related to increased interest by DEA registrants in the use of hallucinogenic controlled substances for research and clinical trial purposes.” The proposal further states: “DEA firmly believes in supporting regulated research of schedule I controlled substances. Therefore, the APQ increases reflect the need to fulfill research and development requirements in the production of new drug products, and the study of marijuana effects in particular, as necessary steps toward potential Food and Drug Administration (FDA) approval of new drug products.”

While the DEA regularly adjusts APQs, the language used by the DEA is notable, as it expressly highlights the prospect of new drug products using the substances. The extent of the increases is also significant. The DEA is proposing to increase production of marijuana to 2 million grams (approximately 4,400 pounds), which represents a 500,000-gram increase from its initial APQ for 2021. The DEA is also seeking to manufacture 500,000 grams of cannabis extract, which is more than twice its original APQ. With regard to psilocybin and psilocin, production will also expand significantly under the DEA proposal. The APQ for psilocybin would increase to 1,500 grams, which is a 2,900 percent increase. The DEA is proposing to produce 1,000 grams of psilocin, up from its initial 2021 proposal of 50 grams.

What’s Next?

The DEA proposal was published in the Federal Register on September 2, 2021, and interested parties had 30 days to submit comments. Based on comments received in response to the proposal, the DEA Administrator may hold a public hearing on one or more issues raised.

While cannabis legalization continues to dominate headlines, psychedelics have the potential to be cannabis 2.0 – not because of their recreational use, but for their increasingly confirmed efficacy in medical treatment of mental health issues like PTSD, depression, anxiety (including end-of-life anxiety), and addiction, which may result in inevitable legalization. Scarinci Hollenbeck’s Cannabis Law Group is closely monitoring this rapidly evolving area of law.

If you have questions, please contact us

If you have any questions or if you would like to discuss the matter further, please contact Dan McKillop or the Scarinci Hollenbeck attorney with whom you work, at 201-896-4100.

No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.

Scarinci Hollenbeck, LLC, LLC

Related Posts

See all
Scarinci Hollenbeck Expands NYC Real Estate and Litigation Practices ADDING four litigators post image

Scarinci Hollenbeck Expands NYC Real Estate and Litigation Practices ADDING four litigators

NYC Real Estate and Litigation Attorney Ryan O. Miller and Team Join Scarinci Hollenbeck, LLC New York City, NY – August 13, 2025 – Scarinci Hollenbeck, LLC has strengthened its Real Estate and Litigation practices with the addition of four New York City-based attorneys. Ryan Miller, who joins as a partner, is well known for […]

Author: Scarinci Hollenbeck, LLC

Link to post with title - "Scarinci Hollenbeck Expands NYC Real Estate and Litigation Practices ADDING four litigators"
What is Business Law and Why Is it Important? post image

What is Business Law and Why Is it Important?

Business law plays a critical role in nearly every aspect of running a successful enterprise, from negotiating a commercial lease to drafting employee policies to fulfilling corporate disclosure obligations. Understanding what is business law and your legal obligations can help your business run smoothly and build productive relationships with clients, business partners, regulators, and others. […]

Author: Dan Brecher

Link to post with title - "What is Business Law and Why Is it Important?"
Corporate Transactions: Best Practices for Successful Deals post image

Corporate Transactions: Best Practices for Successful Deals

Corporate transactions can have significant implications for a corporation and its stakeholders. For deals to be successful, companies must act strategically to maximize value and minimize risk. It is also important to fully understand the legal and financial ramifications of corporate transactions, both in the near and long term. Understanding Corporate Transactions The term “corporate […]

Author: Dan Brecher

Link to post with title - "Corporate Transactions: Best Practices for Successful Deals"
How to Conduct a Fair and Legal Employee Termination in 2025 post image

How to Conduct a Fair and Legal Employee Termination in 2025

Ongoing economic uncertainty is forcing many companies to make tough decisions, which includes lowering staff levels. The legal landscape on both the state and federal level also continues to evolve, especially with significant changes to the priorities of the Equal Employment Opportunity Commission (“EEOC”) under the Trump Administration. Terminating an employee is one of the […]

Author: Angela A. Turiano

Link to post with title - "How to Conduct a Fair and Legal Employee Termination in 2025"
Admin Dissolution for Annual Report: What You Need to Know post image

Admin Dissolution for Annual Report: What You Need to Know

While filing annual reports may seem like a nuisance, failing to do so can have significant ramifications. These include fines, reputational harm, and interruption of your business operations. In basic terms, “admin dissolution for annual report” means that a company is dissolved by the government. This happens because it failed to submit its annual report […]

Author: Dan Brecher

Link to post with title - "Admin Dissolution for Annual Report: What You Need to Know"
What Is Antitrust Litigation Law? post image

What Is Antitrust Litigation Law?

Antitrust laws are designed to ensure that businesses compete fairly. There are three federal antitrust laws that businesses must navigate. These include the Sherman Act, the Federal Trade Commission Act, and the Clayton Act. States also have their own antitrust regimes. These may vary from federal regulations. Understanding antitrust litigation helps businesses navigate these complex […]

Author: Robert E. Levy

Link to post with title - "What Is Antitrust Litigation Law?"

No Aspect of the advertisement has been approved by the Supreme Court. Results may vary depending on your particular facts and legal circumstances.

Sign up to get the latest from our attorneys!

Explore What Matters Most to You.

Consider subscribing to our Firm Insights mailing list by clicking the button below so you can keep up to date with the firm`s latest articles covering various legal topics.

Stay informed and inspired with the latest updates, insights, and events from Scarinci Hollenbeck. Our resource library provides valuable content across a range of categories to keep you connected and ahead of the curve.

Let`s get in touch!

* The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form. By providing a telephone number and submitting this form you are consenting to be contacted by SMS text message. Message & data rates may apply. You can reply STOP to opt-out of further messaging.

Sign up to get the latest from the Scarinci Hollenbeck, LLC attorneys!